153 related articles for article (PubMed ID: 27268144)
1. Dynamics of ligand binding to GPCR: Residence time of melanocortins and its modulation.
Rinken A; Veiksina S; Kopanchuk S
Pharmacol Res; 2016 Nov; 113(Pt B):747-753. PubMed ID: 27268144
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous fluorescence anisotropy-based assay for characterization of ligand binding dynamics to GPCRs in budded baculoviruses: the case of Cy3B-NDP-α-MSH binding to MC4 receptors.
Veiksina S; Kopanchuk S; Mazina O; Link R; Lille A; Rinken A
Methods Mol Biol; 2015; 1272():37-50. PubMed ID: 25563175
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence Anisotropy-Based Assay for Characterization of Ligand Binding Dynamics to GPCRs: The Case of Cy3B-Labeled Ligands Binding to MC
Veiksina S; Tahk MJ; Laasfeld T; Link R; Kopanchuk S; Rinken A
Methods Mol Biol; 2021; 2268():119-136. PubMed ID: 34085265
[TBL] [Abstract][Full Text] [Related]
4. Budded baculoviruses as a tool for a homogeneous fluorescence anisotropy-based assay of ligand binding to G protein-coupled receptors: the case of melanocortin 4 receptors.
Veiksina S; Kopanchuk S; Rinken A
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):372-81. PubMed ID: 24095674
[TBL] [Abstract][Full Text] [Related]
5. Characterization of ligand binding to melanocortin 4 receptors using fluorescent peptides with improved kinetic properties.
Link R; Veiksina S; Rinken A; Kopanchuk S
Eur J Pharmacol; 2017 Mar; 799():58-66. PubMed ID: 28132916
[TBL] [Abstract][Full Text] [Related]
6. Assays with Detection of Fluorescence Anisotropy: Challenges and Possibilities for Characterizing Ligand Binding to GPCRs.
Rinken A; Lavogina D; Kopanchuk S
Trends Pharmacol Sci; 2018 Feb; 39(2):187-199. PubMed ID: 29102621
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence anisotropy assay for pharmacological characterization of ligand binding dynamics to melanocortin 4 receptors.
Veiksina S; Kopanchuk S; Rinken A
Anal Biochem; 2010 Jul; 402(1):32-9. PubMed ID: 20302839
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Use of GPCR Modeling and SDM Experiments to Understand Ligand Binding.
Potterton A; Heifetz A; Townsend-Nicholson A
Methods Mol Biol; 2018; 1705():335-343. PubMed ID: 29188570
[TBL] [Abstract][Full Text] [Related]
9. Kinetic evidence for tandemly arranged ligand binding sites in melanocortin 4 receptor complexes.
Kopanchuk S; Veiksina S; Mutulis F; Mutule I; Yahorava S; Mandrika I; Petrovska R; Rinken A; Wikberg JE
Neurochem Int; 2006 Oct; 49(5):533-42. PubMed ID: 16764968
[TBL] [Abstract][Full Text] [Related]
10. Binding Kinetics and Pathways of Ligands to GPCRs.
Strasser A; Wittmann HJ; Seifert R
Trends Pharmacol Sci; 2017 Aug; 38(8):717-732. PubMed ID: 28645833
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological relationships and ligand discovery of G protein-coupled receptors revealed by simultaneous ligand and receptor clustering.
Zhang C; Shao YM; Ma X; Cheong SL; Qin C; Tao L; Zhang P; Chen S; Zeng X; Liu H; Pastorin G; Jiang Y; Chen YZ
J Mol Graph Model; 2017 Sep; 76():136-142. PubMed ID: 28728042
[TBL] [Abstract][Full Text] [Related]
12. Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?
Hothersall JD; Brown AJ; Dale I; Rawlins P
Drug Discov Today; 2016 Jan; 21(1):90-96. PubMed ID: 26226643
[TBL] [Abstract][Full Text] [Related]
13. Molecular Basis of Ligand Dissociation from G Protein-Coupled Receptors and Predicting Residence Time.
Guo D; IJzerman AP
Methods Mol Biol; 2018; 1705():197-206. PubMed ID: 29188564
[TBL] [Abstract][Full Text] [Related]
14. Implementation of fluorescence anisotropy-based assay for the characterization of ligand binding to dopamine D
Allikalt A; Kopanchuk S; Rinken A
Eur J Pharmacol; 2018 Nov; 839():40-46. PubMed ID: 30205112
[TBL] [Abstract][Full Text] [Related]
15. Molecular interaction fingerprint approaches for GPCR drug discovery.
Vass M; Kooistra AJ; Ritschel T; Leurs R; de Esch IJ; de Graaf C
Curr Opin Pharmacol; 2016 Oct; 30():59-68. PubMed ID: 27479316
[TBL] [Abstract][Full Text] [Related]
16. Recognition of privileged structures by G-protein coupled receptors.
Bondensgaard K; Ankersen M; Thøgersen H; Hansen BS; Wulff BS; Bywater RP
J Med Chem; 2004 Feb; 47(4):888-99. PubMed ID: 14761190
[TBL] [Abstract][Full Text] [Related]
17. Structures of G protein-coupled receptors reveal new opportunities for drug discovery.
Cooke RM; Brown AJ; Marshall FH; Mason JS
Drug Discov Today; 2015 Nov; 20(11):1355-64. PubMed ID: 26303408
[TBL] [Abstract][Full Text] [Related]
18. Live-cell microscopy or fluorescence anisotropy with budded baculoviruses-which way to go with measuring ligand binding to M
Tahk MJ; Torp J; Ali MAS; Fishman D; Parts L; Grätz L; Müller C; Keller M; Veiksina S; Laasfeld T; Rinken A
Open Biol; 2022 Jun; 12(6):220019. PubMed ID: 35674179
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin Receptor Accessory Proteins (MRAPs): Functions in the melanocortin system and beyond.
Rouault AAJ; Srinivasan DK; Yin TC; Lee AA; Sebag JA
Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt A):2462-2467. PubMed ID: 28499989
[TBL] [Abstract][Full Text] [Related]
20. Impact, determination and prediction of drug-receptor residence times for GPCRs.
Tautermann CS
Curr Opin Pharmacol; 2016 Oct; 30():22-26. PubMed ID: 27428776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
